Lisa A Damico
Overview
Explore the profile of Lisa A Damico including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
1002
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johnson D, Fehrenbacher L, Novotny W, Herbst R, Nemunaitis J, Jablons D, et al.
J Clin Oncol
. 2023 May;
41(13):2305-2312.
PMID: 37126944
Purpose: To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients And Methods: In a phase II trial,...
2.
Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico L, et al.
Clin Cancer Res
. 2010 Jun;
16(15):3887-900.
PMID: 20554752
Purpose: Inhibition of the vascular endothelial growth factor (VEGF) axis is the basis of all currently approved antiangiogenic therapies. In preclinical models, anti-VEGF blocking antibodies have shown broad efficacy that...
3.
Yeung Y, Wu X, Reyes 2nd A, Vernes J, Lien S, Lowe J, et al.
Cancer Res
. 2010 Apr;
70(8):3269-77.
PMID: 20354184
Bevacizumab [Avastin; anti-vascular endothelial growth factor (VEGF) antibody] is an antiangiogenic IgG approved for treating patients with certain types of colon, breast, and lung cancer. In these indications, bevacizumab is...
4.
Lu Y, Xiang H, Liu P, Tong R, Watts R, Koch A, et al.
MAbs
. 2010 Jan;
1(4):364-9.
PMID: 20068394
Neuropilin-1 (NRP1) acts as a co-receptor for class 3 semaphorins and vascular endothelial growth factor and is an attractive angiogenesis target for cancer therapy. In addition to the transmembrane form,...
5.
Gaudreault J, Fei D, Beyer J, Ryan A, Rangell L, Shiu V, et al.
Retina
. 2007 Nov;
27(9):1260-6.
PMID: 18046235
Purpose: Ranibizumab (Lucentis) is a humanized antigen-binding fragment designed to inhibit all isoforms and active degradation products of vascular endothelial growth factor A (VEGF-A); it is in clinical development for...
6.
Nguyen A, Reyes 2nd A, Zhang M, McDonald P, Wong W, Damico L, et al.
Protein Eng Des Sel
. 2006 Apr;
19(7):291-7.
PMID: 16621915
An AB.Fab (albumin-binding Fab) consists of a Fab and a phage-derived albumin-binding peptide. This molecule is capable of binding both antigen and albumin simultaneously. Using a Fab derived from Herceptin...
7.
Johnson D, Fehrenbacher L, Novotny W, Herbst R, Nemunaitis J, Jablons D, et al.
J Clin Oncol
. 2004 Jun;
22(11):2184-91.
PMID: 15169807
Purpose: To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients And Methods: In a phase II trial,...
8.
Minor D, Monroe D, Damico L, Meng G, Suryadevara U, Elias L
Invest New Drugs
. 2002 Nov;
20(4):389-93.
PMID: 12448656
Objectives: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165,...
9.
Dennis M, Zhang M, Meng Y, Kadkhodayan M, Kirchhofer D, Combs D, et al.
J Biol Chem
. 2002 Jul;
277(38):35035-43.
PMID: 12119302
Plasma protein binding can be an effective means of improving the pharmacokinetic properties of otherwise short lived molecules. Using peptide phage display, we identified a series of peptides having the...
10.
Simmons L, Reilly D, Klimowski L, Shantha Raju T, Meng G, Sims P, et al.
J Immunol Methods
. 2002 May;
263(1-2):133-47.
PMID: 12009210
Many research and clinical applications require large quantities of full-length antibodies with long circulating half-lives, and production of these complex multi-subunit proteins has in the past been restricted to eukaryotic...